Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 3/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770807 | 0.81 | PIM1 (0.34) | PIM1PIM3PIM2 | |
| SCHEMBL19925062 | 0.80 | CCNT1 (0.36) | CCNT1CDK4CCND1CCND3CDK9 | |
| SCHEMBL23770818 | 0.79 | — | — | |
| SCHEMBL23770441 | 0.73 | HTR3E (0.43) | — | |
| SCHEMBL23770622 | 0.71 | CTSL (0.36) | PIM1 | |
| SCHEMBL2130475 | 0.67 | ALOX5 (0.57) | CCNT1CDK4CCND1CCND3CDK9 | |
| SCHEMBL19925230 | 0.67 | HTR3E (0.42) | CCNT1CDK4CCND1CCND3CDK9 | |
| SCHEMBL23770450 | 0.66 | HTR3E (0.43) | CCNT1CDK4CCND1CCND3CDK9 | |
| Hydrochloric Acid SCHEMBL19951396 | 0.66 | HTR3E (0.41) | CCNT1CDK4CCND1CCND3CDK9 | |
| SCHEMBL23770449 | 0.66 | NPC1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |